Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Pharmaceutical Vaneck ETF (PPH)

$56.85 0.36 (0.63%)

10:05 EDT PPH Stock Quote Delayed 15 Minutes

Volume:

Previous Close $57.21

Market Cap 263.68M

PE Ratio -

EPS -

Volume (Avg. Vol.) 11,742

Day's Range 56.85 - 57.19

52-Week Range 52.39 - 64.90

Dividend & Yield 1.03 (1.81%)

PPH Stock Predictions, Articles, and Pharmaceutical Vaneck ETF News

From InvestorPlace
From the Web

What Lies in Store for Pharma ETFs?

By Zacks Investment Research Nov 27, 2017

Pharma stocks have done well this year; what lies ahead?

Buy Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Before Q2 Earnings

By Richard Saintvilus, InvestorPlace Contributor Aug 1, 2017

Teva Pharmaceutical is shedding assets and beginning to get synergies from its M&A. TEVA stock looks like a compelling trade.

The 10 Best Pharma Stocks Under President Donald Trump

By Josh Enomoto, InvestorPlace Contributor Nov 17, 2016

The world was shocked by Donald Trump's surprise victory, but few equities will benefit as much as big pharma stocks.

3 Ways to Play Healthcare’s Hot Stocks

By David Fabian, FMD Capital Management Jul 24, 2014

Broad plays on healthcare stocks have done well historically, but investors can get some significant juice out of more targeted plays.

Disruptive GW Pharmaceuticals Is Exempt from Big Pharma’s Volatility

From InvestorPlace Apr 30, 2019

Medical cannabis’ cheap costs and natural uses will benefit GW Pharmaceuticals stock in the long run, keeping GWPH stock growing.

Bristol-Myers Squibb Reports Earnings Tomorrow. Here’s What to Expect.

From Barron's Apr 24, 2019

Bristol-Myers Squibb stock is down 13% this year, partly because investors have been skeptical of its move to buy biotech company Celgene.

Does Recent Weakness in AbbVie Stock Make It a Buy? 3 Pros, 3 Cons

From InvestorPlace Mar 21, 2019

ABBV stock offers huge reward with its 5.3% dividend yield, and also huge risk with Humira's generic competition. What's the right play?

A Look At Pharma ETFs Post Q4 Results

From TalkMarkets Feb 7, 2019

The strong results but downbeat guidance led to decent returns in the pharma ETFs over the past month. Here they are in detail.

Don’t Punish Gilead Stock for Doing Its Job

From InvestorPlace Dec 10, 2018

Unfavorable PR and government investigations have hampered GILD stock, but its Hepatitis C breakthrough warrants serious consideration.

Beaten-Down Pharma ETFs to Buy Post Q3 Results

From TalkMarkets Nov 6, 2018

Total earnings for 76.7% of the total healthcare market capitalization are up 11% on revenue growth of 7.2%. The growth rates seem unimpressive when compared with some of the other sectors.

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!